InsiderTrades

Form 4 for MET MetLife

Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-13 · accession 0001099219-24-000270 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-12-17 2024-12-13 MET DEBEL MARLENE EVP, CRO M - OptEx $39.26 +22.8K 131.3K +21% +$895.4K
D 2024-12-17 2024-12-13 MET DEBEL MARLENE EVP, CRO S - Sale+OE $82.88 -22.8K 108.5K -17% -$1.89M
DM 2024-12-17 2024-12-13 MET DEBEL MARLENE EVP, CRO M - OptEx $0.00 -22.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-13 M A 13,107 $34.33 121,614 D — —
2 Common Common Stock 2024-12-13 M A 9,703 $45.91 131,317 D — —
3 Common Common Stock 2024-12-13 S D 22,810 $82.88 108,507 D — — (F1) The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $82.83 to $82.931, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
4 Derivative Employee Stock Options (right to buy) 2024-12-13 M D 13,107 $0.00 0 D $34.33 · — to 2026-02-22 13,107 Common Stock (F2) The options became exercisable in three substantially equal installments on February 23, 2017, 2018, and 2019.
5 Derivative Employee Stock Options (right to buy) 2024-12-13 M D 9,703 $0.00 0 D $45.91 · — to 2025-02-23 9,703 Common Stock (F3) The options became exercisable in three substantially equal installments on February 24, 2016, February 24, 2017, and February 27, 2018.